一名接受芬戈莫德治疗复发型多发性硬化症的男性患急性淋巴细胞白血病
Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis.
作者信息
Cohan Stanley, Godwin John, Gaedeke Leah
机构信息
Providence Health & Services, Portland, OR, USA.
出版信息
J Investig Med High Impact Case Rep. 2015 Mar 9;3(1):2324709615575551. doi: 10.1177/2324709615575551. eCollection 2015 Jan-Mar.
Abstract
A man with relapsing multiple sclerosis, treated with fingolimod 0.5 mg/d for 15 months, developed acute lymphoblastic leukemia and died 4 months after immune ablation and bone marrow allograft, from graft versus host disease. To our knowledge, this is the first case of acute lymphoblastic leukemia reported in a patient treated with fingolimod. Although no causal relationship can be established between fingolimod use and acute lymphoblastic leukemia risk in this single case, future surveillance for lymphatic cell malignancies in patients treated with fingolimod appears justified.
摘要
一名复发型多发性硬化症男性患者，接受每日0.5毫克芬戈莫德治疗15个月后，患上急性淋巴细胞白血病，并在免疫消融和骨髓同种异体移植后4个月死于移植物抗宿主病。据我们所知，这是首例接受芬戈莫德治疗的患者发生急性淋巴细胞白血病的病例报告。尽管在这一单个病例中无法确定使用芬戈莫德与急性淋巴细胞白血病风险之间存在因果关系，但对接受芬戈莫德治疗的患者进行未来淋巴细胞恶性肿瘤监测似乎是合理的。
相似文献
1
Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis.一名接受芬戈莫德治疗复发型多发性硬化症的男性患急性淋巴细胞白血病
J Investig Med High Impact Case Rep. 2015 Mar 9;3(1):2324709615575551. doi: 10.1177/2324709615575551. eCollection 2015 Jan-Mar.
2
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.芬戈莫德治疗复发缓解型多发性硬化症的安全性和疗效（FREEDOMS II）：一项双盲、随机、安慰剂对照、3 期临床试验。
Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28.
3
Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.口服芬戈莫德治疗复发缓解型多发性硬化症 评价：Kappos L、Radue E-M、O'Connor P 等人。口服芬戈莫德治疗复发型多发性硬化症的安慰剂对照试验。《新英格兰医学杂志》2010；362：387-401；以及 Cohen JA、Barkhof F、Comi G 等人。口服芬戈莫德或肌肉内干扰素治疗复发型多发性硬化症。《新英格兰医学杂志》2010；362：402-15。
Expert Opin Pharmacother. 2010 Jul;11(10):1777-81. doi: 10.1517/14656566.2010.481671.
4
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS).既往治疗状态及停药原因对芬戈莫德与肌内注射干扰素β-1a疗效和安全性的影响：复发缓解型多发性硬化症中注射用干扰素与口服芬戈莫德对比试验（TRANSFORMS）的亚组分析
Mult Scler Relat Disord. 2014 May;3(3):355-63. doi: 10.1016/j.msard.2013.11.006. Epub 2013 Dec 12.
5
Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.随机、开放性研究评估多发性硬化复发患者在更换前期疾病修正治疗药物后使用芬戈莫德的患者报告结局：EPOC 研究的原理和设计。
J Med Econ. 2013 Jul;16(7):859-65. doi: 10.3111/13696998.2013.802239. Epub 2013 May 20.
6
Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study.既往治疗状态及停药原因对芬戈莫德疗效和安全性的影响：芬戈莫德每日口服疗法治疗多发性硬化症疗效评估（FREEDOMS）研究的亚组分析
Mult Scler Relat Disord. 2014 May;3(3):341-9. doi: 10.1016/j.msard.2013.10.006. Epub 2013 Nov 5.
7
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.从注射疗法直接转换为口服芬戈莫德的疗效：复发型多发性硬化症的随机、开放标签、多中心、评估患者结局（EPOC）研究结果
Mult Scler Relat Disord. 2014 Sep;3(5):607-19. doi: 10.1016/j.msard.2014.06.005. Epub 2014 Jul 4.
8
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.芬戈莫德停药后，4例复发缓解型多发性硬化症患者出现严重疾病复发。
J Neuroimmunol. 2015 May 15;282:118-22. doi: 10.1016/j.jneuroim.2015.03.022. Epub 2015 Apr 7.
9
Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.淋巴瘤样丘疹病：一名接受芬戈莫德治疗多发性硬化症的患者所患的一种皮肤淋巴细胞增殖性疾病。
Mult Scler. 2016 Jan;22(1):122-4. doi: 10.1177/1352458515597568. Epub 2015 Jul 28.
10
Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.口服芬戈莫德治疗复发性多发性硬化症患者。
Int J Clin Pract. 2011 Aug;65(8):887-95. doi: 10.1111/j.1742-1241.2011.02721.x. Epub 2011 Jun 16.
引用本文的文献
1
Breast Carcinoma After Ocrelizumab Therapy in Multiple Sclerosis Patients: A Case Series and Literature Review.多发性硬化症患者接受奥瑞珠单抗治疗后发生乳腺癌：病例系列及文献综述
J Cent Nerv Syst Dis. 2021 Sep 2;13:11795735211037785. doi: 10.1177/11795735211037785. eCollection 2021.
2
Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study.芬戈莫德在伊朗复发缓解型多发性硬化症患者中的安全性和有效性：一项开放标签研究。
Caspian J Intern Med. 2021 Apr;12(3):263-274. doi: 10.22088/cjim.12.3.263.
3
Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs.多发性硬化症患者的癌症风险：疾病修正药物的潜在影响。
CNS Drugs. 2018 Oct;32(10):939-949. doi: 10.1007/s40263-018-0564-y.
本文引用的文献
1
Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis.鞘氨醇-1-磷酸受体通过与原发性免疫缺陷、慢性淋巴细胞白血病和多发性硬化症相关的信号成分控制 B 细胞迁移。
J Allergy Clin Immunol. 2014 Aug;134(2):420-8. doi: 10.1016/j.jaci.2014.01.037. Epub 2014 Mar 26.
2
Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis.0至14岁急性淋巴细胞白血病患者按十年划分的生存改善情况：一项监测、流行病学和最终结果（SEER）分析
Sci Rep. 2014 Feb 27;4:4227. doi: 10.1038/srep04227.
3
Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia.FTY720 在费城阳性和阴性 B 细胞系急性淋巴细胞白血病异种移植模型中的体内疗效差异。
PLoS One. 2012;7(5):e36429. doi: 10.1371/journal.pone.0036429. Epub 2012 May 3.
4
Elevated β-arrestin1 expression correlated with risk stratification in acute lymphoblastic leukemia.β-arrestin1 表达升高与急性淋巴细胞白血病的危险分层相关。
Int J Hematol. 2011 Apr;93(4):494-501. doi: 10.1007/s12185-011-0824-9. Epub 2011 Apr 12.
5
FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells.FTY720 诱导急性淋巴细胞白血病细胞发生不依赖半胱氨酸蛋白酶的细胞死亡。
Autophagy. 2011 Jul;7(7):707-15. doi: 10.4161/auto.7.7.15154. Epub 2011 Jul 1.
6
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.一项口服芬戈莫德治疗复发性多发性硬化的安慰剂对照试验。
N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.
7
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.口服芬戈莫德（FTY720）在多发性硬化症中的作用机制。
Clin Neuropharmacol. 2010 Mar-Apr;33(2):91-101. doi: 10.1097/WNF.0b013e3181cbf825.
8
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.FTY720疗法对多发性硬化症中的T细胞亚群具有不同的作用。
Neurology. 2008 Oct 14;71(16):1261-7. doi: 10.1212/01.wnl.0000327609.57688.ea.
9
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.FTY720在慢性淋巴细胞白血病和淋巴细胞白血病/淋巴瘤方面展现出了有前景的临床前活性。
Blood. 2008 Jan 1;111(1):275-84. doi: 10.1182/blood-2006-10-053884. Epub 2007 Aug 29.
10
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.FTY720，一种治疗急变期慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病的新选择。
J Clin Invest. 2007 Sep;117(9):2408-21. doi: 10.1172/JCI31095.
Zotero 插件